The UK’s drug pricing and reimbursement watchdog has issued draft guidance recommending stopping National Health Service funding for Amgen’s Lumakras for new patients. The move, reported after the watchdog’s review, reflects the ongoing pressure on National Institute for Health and Care Excellence pathways as authorities demand cost-effectiveness evidence. While the specific committee reasoning wasn’t fully detailed in the prompt, the recommendation indicates that payer access for high-cost oncology medicines remains fragile, particularly when endpoints or real-world value are questioned. For biotech, the case is a reminder that even late-stage clinical progress may not translate into swift commercial uptake without reimbursement alignment.